WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration 30 June 2016
Ready. Raise. Rise. Campaign 06 May 2016
Bristol-Myers Squibb reports first quarter financial results 28 April 2016
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc. 23 March 2016
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies 07 March 2016
Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare 22 February 2016
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement 16 February 2016
Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening 01 February 2016
Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare 18 December 2015
Bristol-Myers Squibb and UCLA enter into a collaboration agreement 14 December 2015
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M 01 December 2015
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc. 02 November 2015
Bristol-Myers Squibb reports third quarter financial results 27 October 2015
Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC) 12 October 2015
Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement 25 September 2015
Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research 10 September 2015
Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. 04 August 2015
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America 16 April 2015
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases 24 March 2015
FDA approves Opdivo (nivolumab) for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer 05 March 2015
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
  • A new technology offers treatment for HIV infection through a single injection

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb
  4. The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.